DROTAVERINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H31NO4
Molecular Weight	397.5072
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC1=CC=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1OCC

InChI

InChIKey=OMFNSKIUKYOYRG-MOSHPQCFSA-N

InChI=1S/C24H31NO4/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20/h9-10,13-16,25H,5-8,11-12H2,1-4H3/b20-13-

HIDE SMILES / InChI

Molecular Formula	C24H31NO4
Molecular Weight	397.5072
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.practo.com/medicine-info/drotaverine-96-api | https://www.ncbi.nlm.nih.gov/pubmed/27738091 | https://www.ncbi.nlm.nih.gov/pubmed/27879007

Drotaverine, an antispasmodic drug, is a synthetic derivative of the natural isoquinoline alkaloid of Papaver somniferum, papaverine. It inhibits cyclic-3',5'-nucleotide-phophodiesterase (PDE) enzymes with concentration-dependent specificity, in addition, it behaves as a L-type voltage- operated calcium channel (L-VOCC) blocker. Drotaverin also acts as a cytostatic compound for several human tumor cell lines. Drotaverine is an effective medicine to treat spasm or twitches of the smooth muscles in the stomach and heart. It is used to relieve pain caused due to irritable bowel syndrome, headache, menstrual periods, and is also used to relieve cervical spasm during labor.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 4 52 Target ID: CHEMBL2093863 Sources: https://www.belmedpreparaty.com/product/anot.php?anat_id=396&lang_id=2 \| https://www.drugbank.ca/drugs/DB06751	Inhibitor 8297

PubMed

Title	Date	PubMed
Pharmacokinetics and bioavailability of drotaverine in humans.	1996 Jul-Sep	8980918
[Acute intermittent porphyria and oral contraception. Case report].	2006 Mar	16871841
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	2010 Dec	20829430

Patents

Sample Use Guides

In Vivo Use Guide

The drug is administered for interior use. 1-2 tablets (0.04—0.08 g) 2—3 time a day. In children under 6 0.01—0.02 g 1—2 times a day, in children of 6—12 years old — 0.02 g 1—2 times a day. In children after 12 the adult dose.

Route of Administration: Oral

In Vitro Use Guide

Drotaverin also acts as a cytostatic compound for several human tumor cell lines and nonmalignant mouse fibroblasts, and EC50 values as low as 3.0 μM were observed in SRB assays for HT-29 human colorectal carcinoma cells.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:54:35 UTC 2023` Edited by `admin` on `Fri Dec 15 15:54:35 UTC 2023`
Record UNII	98QS4N58TW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DROTAVERINE

Official Name

English

DROTIN

Brand Name

English

DROTAVERINE [MI]

Common Name

English

(Z)-1-(3,4-DIETHOXYBENZYLIDENE)-6,7-DIETHOXY-1,2,3,4-TETRAHYDROISOQUINOLINE

Systematic Name

English

Drotaverine [WHO-DD]

Common Name

English

DROTAVERIN

Common Name

English

DROTAVERINE [MART.]

Common Name

English

drotaverine [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA03AD02